Less Frequent GLP-1 Shots May Sustain Weight Loss, Small Study Finds
TL;DR Summary
A small study of 30 adults suggests that reducing GLP-1 injections (tirzepatide or semaglutide) to intervals of 2–6 weeks can help maintain weight loss and improve health markers. Participants averaged about 36 weeks on reduced dosing with most keeping BMI stable; four regained some weight (largest gain 8 lb). Experts say tapering isn’t right for everyone and larger trials are needed, but this approach could lower long-term costs and treatment burden when paired with lifestyle changes.
- Ozempic, Wegovy: Weight Loss May be Maintained with Fewer GLP-1 Shots Healthline
- Most Patients Keep Weight Off With Fewer GLP-1 Shots, Study Finds The New York Times
- New analysis of GLP-1 drugs suggests people who stopped using medications regained 60% of weight lost abcnews.com
- GLP-1 medication changes may support long-term weight management Medical Xpress
- Weight Regain Seen After Cessation of GLP-1 Receptor Agonists in Adults With Overweight, Obesity Optometry Advisor
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
41 min
vs 42 min read
Condensed
99%
8,213 → 76 words
Want the full story? Read the original article
Read on Healthline